Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

Insights from strategists and analysts can greatly influence market sentiment and investment strategies. CNBC's Halftime ...

Detailed price information for Kymera Therapeutics Inc (KYMR-Q) from The Globe and Mail including charting and trades.

Some two dozen biotech developers of PROTACs, molecular glues and other types of protein-degrading drugs have sprung up over ...

Sabic to close UK cracker, plastics recycler Novoloop raises funds, Kymera strikes molecular glue deal, and more ...

Gilead Sciences Inc. (NASDAQ:GILD) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement ...

Gilead will make an upfront payment of up to $85 million, with additional payments contingent on future development milestones and product sales, plus tiered royalties on net product sales. Kymera’s ...

See disclosure here or remove ads. Oppenheimer adjusted its model to reflect the timeline shift in the IRAK4 program, modestly reduced probability of success, and dilution from a $250 million equity ...

Investing.com -- Kymera Therapeutics’ growing roster of partnerships continues to reinforce its long-term value, according to Oppenheimer, despite a setback in one of its programs. The firm reiterated ...